| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7767675 | NOVARTIS PHARM | Imidazotriazines and imidazopyrimidines as kinase inhibitors |
Nov, 2027
(3 years from now) | |
| US8461330 | NOVARTIS PHARM | Imidazotriazines and imidazopyrimidines as kinase inhibitors |
Nov, 2027
(3 years from now) | |
| US8420645 | NOVARTIS PHARM | Salts of 2-fluoro-N-methyl-4-[7-(quinolin-6-yl-methyl)-imidazo[1,2-b][1,2,4]triazin-2-yl]benzamide and processes related to preparing the same |
Jun, 2031
(7 years from now) | |
| US10596178 | NOVARTIS PHARM | Tablet formulation of 2-fluoro-N-methyl-4-[7-(quinolin-6-ylmethyl) imidazo [1,2-B] [1,2,4] triazin-2-yl] benzamide |
Jul, 2035
(11 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8901123 | NOVARTIS PHARM | Salts of 2-fluoro-N-methyl-4-[7-(quinolin-6-yl-methyl)-imidazo[1,2-B][1,2,4]triazin-2-yl]benzamide and processes related to preparing the same |
May, 2029
(5 years from now) | |
Tabrecta is owned by Novartis Pharm.
Tabrecta contains Capmatinib Hydrochloride.
Tabrecta has a total of 5 drug patents out of which 0 drug patents have expired.
Tabrecta was authorised for market use on 06 May, 2020.
Tabrecta is available in tablet;oral dosage forms.
Tabrecta can be used as use for the treatment of patients with metastatic non-small cell lung cancer (nsclc) with a mesenchymal-epithelial transition (met) exon 14 skipping mutation.
Drug patent challenges can be filed against Tabrecta from 06 May, 2024.
The generics of Tabrecta are possible to be released after 22 July, 2035.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | May 06, 2025 |
| Orphan Drug Exclusivity(ODE-291) | May 06, 2027 |
Drugs and Companies using CAPMATINIB HYDROCHLORIDE ingredient
NCE-1 date: 06 May, 2024
Market Authorisation Date: 06 May, 2020
Treatment: Use for the treatment of patients with metastatic non-small cell lung cancer (nsclc) with a mesenchymal-epithelial transition (met) exon 14 skipping mutation
Dosage: TABLET;ORAL
TABRECTA family patents
